http://www.supernus.com/ http://finance.yahoo.com/q/ks?s=SUPN+Key+Statistics Focusing on the Future of CNS Diseases by Building on Current Successes
Our vision is to become a leading specialty pharmaceutical company focused on treating CNS disorders. Key elements of our strategy to achieve this vision are to:
Build in-house sales and marketing capabilities-focused on specialty markets in the United States-to promote, when approved, SPN-538 and SPN-804 for the treatment of epilepsy
Advance our product candidates in our psychiatry portfolio, including SPN-812 for the treatment of ADHD and SPN-810 for the treatment of impulsive aggression in ADHD
Develop differentiated products by applying our technologies to known drug compounds; we intend to leverage these proprietary and in-licensed technologies and expand our patent portfolio to further develop and protect our diverse pipeline of product candidates
Establish strategic partnerships to accelerate and maximize the potential of our product candidates worldwide; we will continue to seek strategic collaborations with other pharmaceutical companies to commercialize our product candidates outside the United States
Leverage our expertise to develop and commercialize our broad product portfolio; we will continue to evaluate and develop additional CNS product candidates that we believe have significant commercial potential through our internal research and development efforts or, if appropriate, external collaborations
